Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series

McCormack, Valerie A; Joffe, Maureen; van den Berg, Eunice; Broeze, Nadine; dos Santos Silva, Isabel; Romieu, Isabelle; Jacobson, Judith S; Neugut, Alfred I; Schüz, Joachim; Cubasch, Herbert

doi:10.1186/bcr3478

Table 2 Distribution of ER, PR, HER2, and their combinations by woman and tumor characteristics

From: Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series

		ER status			PR status			HER2 status			ER, PR, and HER2 status number of women				ER, PR, and HER2 status row distribution (%)
		Number positive	Number negative	% ER negative	Number positive	Number negative	% PR negative	Number positive	Number negative	% HER2 positive	Luminal A	Luminal B	HER2P-enriched	TRN	Luminal A	Luminal B	HER2P-enriched	TRN
All women		688	375	35.3†	559	499	47.2†	756	265	26.0†	545	149	116	209	53.5	14.6	11.4	20.5
Age	<40	100	54	35.1	84	71	45.8	102	48	32.0	77	29	19	25	51.3	19.3	12.7	16.7
	40–49	177	85	32.4	148	113	43.3	173	77	30.8	128	47	30	45	51.2	18.8	12.0	18.0
	50–59	149	121	44.8	107	162	60.2	199	59	22.9	123	28	31	75	47.9	10.9	12.1	29.2
	60–69	134	58	30.2	106	83	43.9	141	42	23.0	109	22	20	31	59.9	12.1	11.0	17.0
	70–79	90	41	31.3	82	49	37.4	96	31	24.4	74	19	12	22	58.3	15.0	9.5	17.3
	≥80	38	16	29.6	32	21	39.6	45	8	15.1	34	4	4	11	64.2	7.6	7.6	20.8
Calendar year	2006–2007	86	60	41.1	72	72	50.0	87	37	29.8	66	16	21	21	53.2	12.9	16.9	16.9
	2008–2009	241	144	37.4	186	198	51.6	263	116	30.6	183	65	51	80	48.3	17.2	13.5	21.1
	2010–2012	361	171	32.1	301	229	43.2	406	112	21.6	296	68	44	108	57.4	13.2	8.5	20.9
Stage	I	43	13	23.2	41	16	28.1	40	14	25.9	34	10	4	6	63.0	18.5	7.4	11.1
	II	319	130	29.0	262	184	41.3	345	95	21.6	262	60	35	81	59.8	13.7	8.0	18.5
	III	271	202	42.7	218	254	53.8	314	133	29.8	207	68	65	107	46.3	15.2	14.5	23.9
	IV	55	30	35.3	38	45	54.2	57	23	28.8	42	11	12	15	52.5	13.8	15.0	18.8
Tumor grade	1	89	12	11.9	76	25	24.8	84	15	15.2	76	12	3	8	76.7	12.1	3.0	8.1
	2	331	109	24.8	278	161	36.7	332	96	22.4	276	60	36	55	64.6	14.1	8.4	12.9
	3	189	207	52.3	148	246	62.4	264	125	32.1	138	61	64	125	35.6	15.7	16.5	32.2
	Missing	79	47	37.3	57	67	54.0	76	29	27.6	55	16	13	21	52.4	15.2	12.4	20.0
Ethnicity	Black	606	351	36.7	492	461	48.4	679	240	23.1	481	131	109	196	52.5	14.3	11.9	20.4
	White	32	8	20.0	27	13	32.5	29	9	23.7	24	7	2	5	63.2	18.4	5.3	13.2
	Colored	30	9	23.1	26	13	33.3	30	8	21.1	26	5	3	4	68.4	13.2	7.9	10.5
	Asian	15	5	36.7	12	8	40.0	14	5	25.3	11	4	1	3	57.9	21.1	6.3	15.8

Note: Percentages are among women with known receptor status. Numbers missing are provided in Table 1.
†Percentages (95% confidences intervals) are 35.3 (32.4 to 38.2) for ERN, 47.2 (44.2 to 50.2) for PRN, and 26.0 (23.3 to 28.6) for HER2P.

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com

Breast Cancer Research

Contact us